fngr20170831

0001697884-20-000019.txt : 20200619 0001697884-20-000019.hdr.sgml : 20200619 20200619143614 ACCESSION NUMBER: 0001697884-20-000019 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20200430 FILED AS OF DATE: 20200619 DATE AS OF CHANGE: 20200619 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VITASPRING BIOMEDICAL CO. LTD. CENTRAL INDEX KEY: 0001697884 STANDARD INDUSTRIAL CLASSIFICATION: LEATHER & LEATHER PRODUCTS [3100] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-216465 FILM NUMBER: 20975351 BUSINESS ADDRESS: STREET 1: 400 SPECTRUM CENTER DR. #1620 CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 13239854212 MAIL ADDRESS: STREET 1: 400 SPECTRUM CENTER DR. #1620 CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: Shemn Corp. DATE OF NAME CHANGE: 20170210 10-Q 1 vsbc10-qapril2020.htm fngr20170831_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10−Q

(Mark One)


⌧	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: April 30, 2020


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to _____________

Commission File Number: 333-216465

VITASPRING BIOMEDICAL CO. LTD.

(Exact Name of Registrant as Specified in Its Charter)


Nevada		37-1836726

(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

400 Spectrum Center Dr. #1620

Irvine, CA 92618  

(Address of principal executive offices, Zip Code)

(949)202-9235

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ⌧ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


	Large accelerated filer ☐	Accelerated filer ☐
	Non-accelerated filer ☐ (Do not check if a smaller reporting company)	Smaller reporting company ⌧
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ⌧

The number of shares outstanding of each of the issuer’s classes of common stock, as of April 30, 2020 is as follows:


Class of Securities		Shares Outstanding
Common Stock, $0.001 par value		10,902,006

EXPLANATORY NOTE

On June 15, 2020, the Company filed a “Notification of Late Filing” on Form 12b-25 pursuant to Rule 12b-25 of the Exchange Act to further delay the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended April 30, 2020. In reliance upon the Securities and Exchange Commission’s Order under Section 36 of the Securities Exchange Act of 1934 Granting Exemptions From Specified Provisions of the Exchange Act and Certain Rules Thereunder dated March 4, 2020 (Release No. 34-88318) as modified and superseded by a new SEC order issued on March 25, 2020 (Release No. 34-88465) (collectively, the “Order”) we have further delayed the filing of our Quarterly Report on Form 10-Q for the quarter ended April 30, 2020 (the “Report”) due to circumstances related to the coronavirus disease 2019 (“COVID-19”).]

VITASPRING BIOMEDICAL CO. LTD.

Quarterly Report on Form 10-Q

For the Quarter Ended April 30, 2020

TABLE OF CONTENTS


PART I – FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements - unaudited	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17
Item 4.	Controls and Procedures	17

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	18
Item 1A.	Risk Factors	18
Item 2.	Unregistered Sale of Equity Securities and Use of Proceeds	18
Item 3.	Defaults Upon Senior Securities	18
Item 4.	Mine Safety Disclosures	18
Item 5.	Other Information	18
Item 6.	Exhibits	18

Signatures		18

PART I

FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

VITASPRING BIOMEDICAL CO. LTD.

Consolidated Condensed Balance Sheets

APRIL 30, 2020 AND JANUARY 31, 2020


ASSETS
	(Unaudited)
	April 30, 2020	January 31, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 893	$ -

Total current assets	893	-

Total assets	$ 893	$ -

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES
Credit card liability	$ 8,660	$ -
Advance from related party	9,978	-

Total current liabilities	18,638	-

Total liabilities	18,638	-

COMMITMENTS AND CONTINGENCIES	-	-

STOCKHOLDERS' DEFICIT
Common stock, $0.001 par value, 225,000,000 and
75,000,000 shares, respectively authorized
10,902,006 and 10,902,006 shares, respectively issued
and outstanding	3,634	3,634
Additional paid-in capital	18,262	18,262
Accumulated deficit	(39,641)	(21,896)

Total stockholders' deficit	(17,745)	-

Total liabilities and stockholders' deficit	$ 893	$ -

See Accompanying Notes to the Condensed Consolidated Financial Statements (Unaudited)

VITASPRING BIOMEDICAL CO. LTD.

Consolidated Condensed Statements of Operations

THREE MONTH ENDED APRIL 30, 2020 AND 2019

(UNAUDITED)


	Three months ended
	April 30, 2020	April 30, 2019

Revenues	$ -	$ 7,215

Cost of goods sold	-	904

Gross profit from operations	-	6,311

Operating expenses:
Selling, general and administrative expenses (Schedule I)	17,745	14,821
Loss from operations	(17,745)	(8,510)

Net loss from operations before
provision for income tax benefit (expense)	(17,745)	(8,510)

Provision for income tax benefit (expense)	-	-

Net loss	$ (17,745)	$ (8,510)

Net loss per share: Basic and diluted	$ -	$ -

Weighted average number of
shares outstanding: Basic and
diluted	10,902,006	10,902,006

See Accompanying Notes to the Condensed Consolidated Financial Statements (Unaudited)

VITASPRING BIOMEDICAL CO. LTD.

Consolidated Condensed Statements of Cash Flows

THREE MONTHS ENDED APRIL 30, 2020 AND 2019

(UNAUDITED)


	Three months ended
	April 30, 2020	April 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (17,745)	$ (8,510)
Adjustments to reconcile net loss to net cash
provided by operating activities:
Depreciation expense	-	112
Changes in assets and liabilities:
Prepaid expenses	-	1,410
Inventory	-	904
#REF!	-	7,600
Credit card liability	8,660	-
Advance from related party	9,978	-

Net cash provided by operating activities	893	1,516

Net increase in cash and cash equivalents	893	1,516

CASH AND CASH EQUIVALENTS, BEGINNING OF THE YEAR	-	105

CASH AND CASH EQUIVALENTS, END OF THE YEAR	$ 893	$ 1,621

Supplemental cash flow disclosures:
Income taxes paid	$ -	$ -
Interest expense paid	$ -	$ -

See Accompanying Notes to the Condensed Consolidated Financial Statements (Unaudited)


VITASPRING BIOMEDICAL CO. LTD. Consolidated Statement of Shareholders' Equity(deficit) THREE MONTHS ENDED APRIL 30, 2020 (UNAUDITED)
	Number of Shares	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total Stockholders' Deficit

Balance, January 31, 2020	10,902,006	$ 3,634	$ 18,262	$ (21,896)	$ -

Net loss	-	-	-	(17,745)	(17,745)

Balance, April 30, 2020	10,902,006	$ 3,634	$ 18,262	$ (39,641)	$ (17,745)

See Accompanying Notes to the Condensed Consolidated Financial Statements (unaudited)

VITASPRING BIOMEDICAL CO. LTD.

Three Months ended April 30, 2020 and 2019

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

Note 1 – ORGANIZATION AND NATURE OF BUSINESS

VitaSpring Biomedical Co., Ltd (formerly Shemn Corp.) (“the Company”) was incorporated in the State of Nevada on September 6, 2016. The Company plans to distribute healthcare related products.

Note 2 – GOING CONCERN

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $39,641 and a positive cash flow from operations amounting to $893 for the three months ended April 30, 2020. The Company had $0 in revenues for the three months ended April 30, 2020. The Company currently has losses and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

Note 3 – SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES

Basis of presentation

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America. The Company’s year-end is January 31.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with the original maturities of three months or less to be cash equivalents. The Company had $893 of cash equivalents as of April 30, 2020.

Prepaid Expenses

Prepaid Expenses are recorded at fair market value. The Company had $0 in prepaid expenses as of April 30, 2020.

Inventories

Inventories are stated at the lower of cost or market. Cost is principally determined using the first-in, first out (FIFO) method. The Company had $0 in raw materials inventory as of April 30, 2020.

Depreciation, Amortization, and Capitalization

The Company records depreciation and amortization when appropriate using straight-line balance method over the estimated useful life of the assets. The Company estimates that the useful life of necessary equipment is 5 years.

Expenditures for maintenance and repairs are charged to expense as incurred. Additions, major renewals and replacements that increase the property's useful life are capitalized. Property sold or retired, together with the related accumulated depreciation is removed from the appropriated accounts and the resultant gain or loss is included in net income.

Accounts Payable

Accounts Payable discloses a liability to a creditor, carried on open account, usually for purchases of goods and services. The Company had $0 in accounts payable as of April 30, 2020.

Credit Card Liability

Credit card liability represents amounts owed to credit card issuers for money borrowed to pay merchants for goods and services based on the cardholder’s promise to pay the card issuer borrowed amounts plus other agreed upon charges. The Company had $8,660 in credit card liability as of April 30, 2020.

Fair Value of Financial Instruments

AS topic 820 "Fair Value Measurements and Disclosures" establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

These tiers include:


Level 1:	defined as observable inputs such as quoted prices in active markets;
Level 2:	defined as inputs other than quoted prices in active markets that are either directly or indirectly observable;
Level 3:	defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The carrying value of cash and the Company’s loan from shareholder approximates its fair value due to their short- term maturity.

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers”. The core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity recognizes revenue in accordance with that core principle by applying the following steps: Step 1: Identify the contract(s) with a customer Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price Step 4: Allocate the transaction price to the performance obligations in the contract Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. Specifically, Section 606-10-50 requires an entity to provide information about: a. Revenue recognized from contracts with customers, including the disaggregation of revenue into appropriate categories; b. Contract balances, including the opening and closing balances of receivables, contract assets, and contract liabilities;

c. Performance obligations, including when the entity typically satisfies its performance obligations and the transaction price that is allocated to the remaining performance obligations in a contract; d. Significant judgments, and changes in judgments, made in applying the requirements to those contracts. For the three months ended April 30, 2020, the Company generated $0 in revenue.

Basic Income (Loss) Per Share

The Company computes income (loss) per share in accordance with FASB ASC 260 “Earnings per Share”. Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. As of April 30, 2020, there were no potentially dilutive debt or equity instruments issued or outstanding.

Comprehensive Income

Comprehensive income is defined as all changes in stockholders’ equity (deficit), exclusive of transactions with owners, such as capital investments. Comprehensive income includes net income or loss, changes in certain assets and liabilities that are reported directly in equity such as translation adjustments on investments in foreign subsidiaries and unrealized gains (losses) on available-for-sale securities. As of April 30, 2020, there were no differences between our comprehensive loss and net loss.

Stock-Based Compensation

Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options.

Foreign Currency Translation

The Company’s functional and reporting currency is the U.S. dollar. Transactions may occur in foreign currencies and management has adopted ASC 830, “Foreign Currency Translation Matters”. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non- monetary assets and liabilities denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Average monthly rates are used to translate revenues and expenses. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the statement of operations.

Recent Accounting Pronouncements

Management has reviewed all the recently issued, but not yet effective, accounting pronouncements and does not believe any of these pronouncements will have a material impact on the Company.

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This guidance changes how companies account for certain aspects of share-based payments to employees. Among other things, under the new guidance, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in-capital (“APIC”), but will instead record such items as income tax expense or benefit in the income statement, and APIC pools will be eliminated. Companies will apply this guidance prospectively. Another component of the new guidance allows companies to make an accounting policy election for the impact of forfeitures on the recognition of expense for share-based payment awards, whereby forfeitures can be estimated, as required today, or recognized when they occur. If elected, the change to recognize forfeitures when they occur needs to be adopted using a modified retrospective approach. All of the guidance will be effective for the Company in the fiscal year beginning February 1, 2017. Early adoption is permitted. The Company is currently evaluating the impact of this guidance, if any, on its financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which issued new guidance related to leases that outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new guidance requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new guidance must be adopted using the modified retrospective approach and will be effective for the Company in the fiscal year beginning February 1, 2019. Early adoption is permitted. The Company is currently evaluating the impact of this guidance, if any, on its financial statements and related disclosures. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The guidance requires an entity to measure inventory at the lower of cost or net realizable value, which is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation, rather than the lower of cost or market in the previous guidance. This amendment applies to inventory that is measured using first-in, first-out (FIFO). This amendment is effective for public entities for fiscal years beginning after December 15, 2016, including interim periods within those years. A reporting entity should apply the amendments prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact of this guidance, if any, on its financial statements and related disclosures.

Note 4 – ADVANCE FROM RELATED PARTY

During February 2020, one of the Company’s major shareholders, related party, advanced to the Company $9,978. The advance is unsecured, non-interest bearing and due on demand. The shareholder advance amounted to $9,978 at April 30, 2020.

Note 5 – COMMON STOCK

The number of authorized shares of common stock under the Certificate of Incorporation was 75,000,000, $0.001 par value, when the Company was incorporated on September 6, 2016. The number of authorized shares of common stock under the Certificate of Incorporation was amended to 225,000,000 shares on November 29, 2018.

On January 26, 2017 the Company issued 3,000,000 shares of common stock to a director for cash proceeds of

$3,000 at $0.001 per share par value. Par value was used because company had just begun and had no value beyond par value at this stage.

In March 2018 the Company issued 17,667 shares of common stock for cash proceeds of $515 at $0.03 per share par value.

In April 2018 the Company issued 20,500 shares of common stock for cash proceeds of $587 at $0.03 per share par value.

In May 2018 the Company issued 60,000 shares of common stock for cash proceeds of $1,719 at $0.03 per share par value.

In August 2018 the Company issued 239,166 shares of common stock for cash proceeds of $7,175 at $0.03 per share par value.

In September 2018 the Company issued 112,000 shares of common stock for cash proceeds of $3,360 at $0.03 per share par value.

In October 2018 the Company issued 184,669 shares of common stock for cash proceeds of $5,540 at $0.03 per share par value.

On November 29, 2018, the Company amended its articles of incorporation, to affect a 3 to 1 stock split for the Company. At a special meeting on November 1, 2018, the majority of shareholders approved the amendment to the articles of incorporation. On December 12, 2018, the Company filed an 8-K Form regarding the split procedure. The Stock Split increased the number of shares of common stock from 2,030,000 to 6,090,000 shares. The number of restricted shares of common stock increased from 3,000,000 to 9,000,000 shares. The number of authorized shares of common stock under the Certificate of Incorporation was adjusted to 225,000,000 shares.

There were 10,902,006 shares of common stock issued and outstanding as of January 31, 2019.

Effective on January 21, 2020, Liu Shan Shan, the previous sole officer and director and a majority shareholder of the Company owning a total of 82.55% of the issued and outstanding shares of common stock of the Company, together with all other minority shareholders (31) of the Company owning an aggregate of 17.45% of the issued and outstanding shares of common stock of the Company, entered into stock purchase agreement for the sale of 100% of the outstanding shares of common stock of the Company (10,902,006 shares), to a group of purchasers (32), including Li-Li Chu (2,666,666 shares); the incoming CEO, Chu Pao-Chi (1,666,667 shares); and the incoming Secretary, Kao Chen-Hsiang (800,000 shares).

There were 10,902,006 shares of common stock issued and outstanding as of April 30, 2020.

Note 6 – SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

For the three months ended April 30, 2020, the Company incurred $17,745 in selling, general and administrative expenses. See financial statements – supplementary information schedule I for details.

Note 7 – COMMITMENTS AND CONTINGENCIES

None

Note 8 – INCOME TAXES

The Company adopted the provisions of uncertain tax positions as addressed in ASC 740-10-65-1. As a result of the implementation of ASC 740-10-65-1, the Company recognized no increase in the liability for unrecognized tax benefits. As of April 30, 2020, the Company had net operating loss carry forwards of approximately $39,642 that may be available to reduce future years’ taxable income in varying amounts through 2041. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards.

The valuation allowance at April 30, 2020 was approximately $8,325. The net change in valuation allowance during the three months ended April 30, 2020 was $3,727. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized.

The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of April 30, 2020. All tax years since inception remains open for examination by taxing authorities.

The provision for Federal income tax consists of the following:


April 30, 2020			January 31, 2020
Non-current deferred tax assets	$		- $	- $
Net-operating loss carry forwards		8,325		4,598
Valuation allowance	(8,325)		(4,598)
Net-deferred tax assets	$	-	$	-

The actual tax benefit at the expected rate of 21% differs from the expected tax benefit for the three months ended April 30, 2020 are as follows:


April 30, 2020			January 31, 2020
Computed “expected tax expense (benefit)	$	(3,727)	$	(1,453)
Change in valuation allowance	3,727		1,453
Actual tax expense (benefit)	$	-	$	-

Note 9 – SUBSEQUENT EVENTS

In accordance with SFAS 165 (ASC 855-10) the Company has analyzed its operations subsequent to April 30, 2020 through the date these financial statements were issued and has determined that there were no material subsequent events to disclose in these financial statements.

VitaSpring Biomedical Co., Ltd

NOTES TO THE FINANCIAL

April 30, 2020 (UNAUDITED)

SUPPLEMENTARY INFORMATION


VITASPRING BIOMEDICAL CO., LTD
SUPPLEMENTARY INFORMATION
SCHEDULE I - SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
THREE MONTHS ENDED APRIL 30, 2020 AND 2019
(UNAUDITED)

	Three months ended
	April 30, 2020	April 30, 2019

Bank charges	$ 85	$ 125
Depreciation expense	-	112
Office expense	510	18
Professional fees	17,150	13,156
Rent	-	1,410
Telephone	511	20

Total selling, general and administrative expenses	$ 17,745	$ 14,821

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Caution Regarding Forward-Looking Information

This Quarterly Report on Form 10-Q, including, without limitation, statements containing the words "believes", "anticipates", "expects" and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; and other factors referenced in this and previous filings.

Given these uncertainties, readers of this Form 10-Q and investors are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

Overview

VitaSpring Biomedical Co. Ltd., formerly Shemn Corp., was incorporated in Nevada on September 6, 2016. We are a start-up business company. From inception, we have produced leather fashion design items. Our former President and Director, Liu Shan Shan, showcased our items with potential clients and wholesale purchasers.

Recent Developments

Effective January 21, 2020, Liu Shan Shan, the previous sole officer and director and majority shareholder the Company, entered into stock purchase agreements for the sale of an aggregate of 9,000,000 shares of Common Stock of the Company, representing approximately 82.55% of the issued and outstanding shares of Common Stock of the Company as of such date, to twenty-five (25) purchasers, included Li-Li Chu (2,666,666 shares), a 10% shareholder, and the incoming CEO, Chu Pao-Chi (1,666,667 shares), and the incoming Secretary, Kao Cheng-Hsiang (800,000 shares).

Also effective January 21, 2020, Liu Shan Shan appointed Chu Pao-Chi Chairman of the Board of Directors, and Chief Executive Officer Officer of the Company, Kao Cheng-Hsiang Secretary of the Company, Lin Jer-Li Chief Technical Officer of the Company and Chen Yen Xun Technical Vice-President of the Company.

On March 30, 2020, the Company filed a Certificate of Amendment to its Articles of Incorporation (the "Articles of Amendment") with the Secretary of State of the State of Nevada effecting a name change of the Company to VitaSpring Biomedical Co. Ltd. (the "Corporate Action"). The Corporate Action and the Amended Articles became effective on April 21, 2020, following compliance with notification requirements of the Financial Industry Regulatory Authority.

Business Plan

We have been engaged in the business of developing and marketing products that promote wellness and a healthy lifestyle since 2019. A change of 100% of Company’s ownership occurred effectively on January 21, 2020. As a result, we changed Company name from Shemn Corp. to VitaSpring Biomedical Co. Ltd. on February 17, 2020. Under new management, we ceased producing and distributing leather products. Our sole objective is to develop new drugs of cell medicine. We also plan to establish a GTP cell production center in Taiwan for the production of X.MSC cytopharmaceuticals. The estimated annual output is the amount sufficient for 10,000 people (20 million cells/ does). The GTP cell center is currently under construction. Trial production is expected to begin in June, 2020. Mass production in August, 2020.

We do not sell products in a form for use by consumers although we may, in the future, develop products for use by consumers.

Results of Operations for the Three Months Ended April 30, 2020 Compared to the Three Months Ended April 30, 2019

Revenue and cost of goods sold

For the three months ended April 30, 2020 and April 30, 2020 the Company generated total revenue of $0 and $7,215 from selling products to the customer. The cost of goods sold for the year ended April 30, 2020 and April 30, 2019 was $0 and $904, which represent the cost of raw materials.

Operating expenses

Total operating expenses for the year ended April 30, 2020 and April 30, 2019 were $17,745 and $14,821. The increase was primarily related to increased general and administrative expenses. The operating expenses for the year ended April 30, 2019 including consultants for marketing services and professional fees relating to our SEC filings.

Net Loss

The net loss for the year ended April 30, 2020 and April 30, 2019 was $17,745 and $8,510 accordingly.

Liquidity and Capital Resources and Cash Requirements

At year ended April 30, 2020, the Company had cash of $893. The Company had a working capital deficit of $17,745.

During the year ended April 30, 2020, the Company used $893 of cash in operating activities.

During the year ended April 30, 2020 the Company used no cash in investing activities.

During the year ended April 30, 2020, the Company generated $0 of cash in financing activities.

We cannot guarantee that we will manage to sell all the shares required. We will attempt to raise the necessary funds to proceed with all phases of our plan of operation.

As of the date of this report, the current funds available to the Company will not be sufficient to continue maintaining a reporting status.

Our auditors have issued a “going concern” opinion, meaning that there is substantial doubt we can continue as an on-going business for the next twelve months unless we obtain additional capital. Our only sources for cash at this time are investments by others in this offering, selling our paper dung products and loans from our director. We must raise cash to implement our plan and stay in business.

Management believes that current trends toward lower capital investment in start-up companies pose the most significant challenge to the Company’s success over the next year and in future years. Additionally, the Company will have to meet all the financial disclosure and reporting requirements associated with being a publicly reporting company. The Company’s management will have to spend additional time on policies and procedures to make sure it is compliant with various regulatory requirements, especially that of Section 404 of the Sarbanes-Oxley Act of 2002. This additional corporate governance time required of management could limit the amount of time management has to implement is business plan and impede the speed of its operations.

Limited operating history; need for additional capital

There is no historical financial information about us upon which to base an evaluation of our performance. We are in a start-up stage of operations and have generated limited revenues since inception. We cannot guarantee that we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns due to price and cost increases in services and products.

Off-Balance Sheet Arrangements

We do not maintain any off-balance sheet arrangements, transactions, obligations or other relationships with unconsolidated entities that would be expected to have a material current or future effect upon our financial condition or results of operations.

Going Concern

The consolidated financial statements have been prepared assuming we will continue as a going concern, which contemplates, the realization of assets and satisfaction of liabilities in the normal course of business. We incurred losses from operations of $17,745 and $8,510 for the three months ended April 30, 2019 and 2020, respectively, and had an accumulated deficit of $39,641 at April 30, 2020. In addition, we used cash from operating activities of $893 for the year ended April 30, 2020. These factors raise substantial doubt about our ability to continue as a going concern.

The Company will require additional funding to execute its future strategic business plan. Successful business operations and its transition to attaining profitability are dependent upon obtaining additional financing and achieving a level of revenue adequate to support its cost structure. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

While the Company is attempting to establish an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern, the Company’s cash position may not be adequate to support the Company’s daily operations. Management intends to raise additional funds by seeking equity and/or debt financing; however there can be no assurances that it will be successful in those efforts. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to obtain financing, further implement its business plan, and generate revenues.

There are significant risks and uncertainties which could negatively affect the Company’s operations. These are principally related to the existence of events of default under the Company’s outstanding debt obligations, which could trigger penalties. Furthermore, if our current indebtedness is not restructured, paid or converted into equity, which is at the debt holder’s discretion, our current operations do not generate sufficient cash to pay interest and principal on these obligations when they become due. Accordingly, there can be no assurance that we will be able to pay these or other obligations which we may incur in the future. In the event we are unable to restructure, pay or convert into equity the balance of our outstanding indebtedness, the holders may obtain judgments against us and seek to enforce such judgments against our assets, in which event we will be required to cease our business activities and the equity of our stockholders will be effectively wiped out.

Our only sources of additional funds to meet continuing operating expenses, fund additional research and development and fund additional working capital are through the sale of securities, and/or debt instruments. We are actively seeking additional debt or equity financing, but no assurances can be given that such financing will be obtained or what the terms thereof will be. We may need to discontinue a portion or all of our operations if we are unsuccessful in generating positive cash flow or financing for our operations through the issuance of securities.

Recent Accounting Pronouncements

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. .

In February 2016, the FASB issued ASU 2016-02, Leases, which will amend current lease accounting to require lessees to recognize (i) a lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis, and (ii) a right-of-use asset, which is an asset that represents the lessee's right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 does not significantly change lease accounting requirements applicable to lessors; however, certain changes were made to align, where necessary, lessor accounting with the lessee accounting model. This standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years.

Management has considered all recent accounting pronouncements issued since and their potential effect on our financial statements. The Company's management believes that these recent pronouncements will not have a material effect on the Company's consolidated financial statements.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Item 3 - Quantitative and Qualitative Disclosures About Market Risk

In future periods, the Company may become subject to certain market risks, including changes in interest rates and currency exchange rates. At the present time, the Company has no identified exposure and does not undertake any specific actions to limit exposures, if any.

Item 4 - Controls and Procedures

Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including the Company's president and chief executive officer (who is the Company's principal executive officer) and the Company's chief financial officer, treasurer, and secretary (who is the Company's principal financial officer and principal accounting officer) to allow for timely decisions regarding required disclosure. In designing and evaluating the Company's disclosure controls and procedures, the Company's management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and the Company's management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. The ineffectiveness of the Company's disclosure controls and procedures was due to material weaknesses identified in the Company's internal control over financial reporting, described below.

Management's Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over the Company's financial reporting. In order to evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act of 2002. Our management, with the participation of the Company's principal executive officer and principal financial officer has conducted an assessment, including testing, using the criteria in Internal Control - Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") (2013). Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. This assessment included review of the documentation of controls, evaluation of the design effectiveness of controls, testing of the operating effectiveness of controls and a conclusion on this evaluation.

Based on this evaluation, the Company's management concluded its internal control over financial reporting was effective as of April 30, 2020.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended April 30, 2020, that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any company have been detected.

PART II

OTHER INFORMATION

Item 1 - Legal Proceedings

None

Item 1A – Risk Factors

Item 2 - Sales of Unregistered Equity Securities and Use of Proceeds

None

Item 3 - Defaults upon Senior Securities

None

Item 4 - Mine Safety Disclosures

N/A

Item 5 - Other Information

None


ITEM 6.	EXHIBITS.

The following exhibits are filed as part of this report or incorporated by reference:


Exhibit No.	Description
31.1*	Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101	Materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended November 30, 2018 formatted in Extensible Business Reporting Language (XBRL).

* Filed herewith

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: June 16, 2020	VITASPRING BIOMEDICAL CO. LTD.

	By:	/s/ Chu Pao-Chi
		Chu Pao-Chi Chief Executive Officer

		(Principal Executive Officer)

EX-31.1 2 ex311.htm Converted by EDGARwiz

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Chu Pao-Chi, certify that:


1.	I have reviewed this Form 10-Q of VitaSpring Biomedical Co., Ltd.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: June 19, 2020			By:	/s/ Chu Pao-Chi
				Chu Pao-Chi
				Principal Executive Officer VitaSpring Biomedical Co., Ltd..

EX-31.2 3 ex312.htm Converted by EDGARwiz

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Chu Pao-Chi, certify that:


1.	I have reviewed this Form 10-Q of VitaSpring Biomedical Co., Ltd.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: June 19, 2020			By:	/s/ Chu Pao-Chi
				Chu Pao-Chi
				Principal Financial Officer VitaSpring Biomedical Co., Ltd..

EX-32.1 4 ex321.htm Converted by EDGARwiz

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report of VitaSpring Biomedical Co., Ltd. (the “Company”), on Form 10-Q for the period ended April 30, 2020, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, Chu Pao-Chi, Principal Executive Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

Such Quarterly Report on Form 10-Q for the period ended April 30, 2020, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in such Quarterly Report on Form 10-Q for the period ended April 30, 2020, fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: June 19, 2020	By:	/s/ Chu Pao-Chi
		Chu Pao-Chi
		Principal Executive Officer VitaSpring Biomedical Co., Ltd.

EX-32.2 5 ex322.htm Converted by EDGARwiz

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

(1)

Such Quarterly Report on Form 10-Q for the period ended April 30, 2020, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)



Date: June 19, 2020	By:	/s/ Chu Pao-Chi
		Chu Pao-Chi
		Principal Financial Officer VitaSpring Biomedical Co., Ltd.

EX-101.INS 6 none-20200430.xml 0001697884 2020-02-01 2020-04-30 0001697884 2020-04-30 0001697884 2020-01-31 0001697884 2019-02-01 2019-04-30 0001697884 2020-02-04 2020-04-30 0001697884 2020-02-03 0001697884 2019-02-04 2019-04-30 0001697884 2019-02-03 0001697884 2019-04-30 0001697884 us-gaap:CommonStockMember 2020-01-31 0001697884 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0001697884 us-gaap:RetainedEarningsMember 2020-01-31 0001697884 us-gaap:RetainedEarningsMember 2020-02-01 2020-04-30 0001697884 us-gaap:CommonStockMember 2020-04-30 0001697884 us-gaap:AdditionalPaidInCapitalMember 2020-04-30 0001697884 us-gaap:RetainedEarningsMember 2020-04-30 0001697884 2020-02-08 2020-04-30 0001697884 2020-02-11 2020-04-30 0001697884 2020-01-27 2020-04-30 0001697884 2017-01-26 0001697884 2018-12-12 0001697884 2018-11-29 2018-12-12 0001697884 2020-01-24 2020-04-30 0001697884 2020-01-20 2020-04-30 0001697884 2020-01-20 2020-01-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares 10-Q false 2020-04-30 2021 Q1 VITASPRING BIOMEDICAL CO. LTD. 0001697884 --01-31 Non-accelerated Filer 10902006 Yes No false true true false

893

8660

9978

18638

3634

18262

-39641

-21896

-17745

893

10902006

7215

904

6311

17745

14821

-17745

-8510

-17745

-8510

-17745

-8510

10902006

-17745

-8510

112

1410

904

7600

8660

9978

893

1516

893

1516

105

1621

3634

18262

-21896

10902006

-17745

3634

18262

-39641

-17745

10902006

<h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:12.0pt;page-break-after:avoid;">Note 3 - SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES</h4>   Basis of presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America. The Company's year-end is January 31.   <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:12.0pt;page-break-after:avoid;">Use of Estimates</h4> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.   <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:12.0pt;page-break-after:avoid;">Cash and Cash Equivalents</h4> The Company considers all highly liquid investments with the original maturities of three months or less to be cash equivalents. The Company had $893 of cash equivalents as of April 30, 2020. <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:9.15pt;page-break-after:avoid;">Prepaid Expenses</h4> Prepaid Expenses are recorded at fair market value. The Company had $0 in prepaid expenses as of April 30, 2020.   <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:12.0pt;page-break-after:avoid;">Inventories</h4> Inventories are stated at the lower of cost or market. Cost is principally determined using the first-in, first out (FIFO) method. The Company had $0 in raw materials inventory as of April 30, 2020.   <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:12.0pt;page-break-after:avoid;">Depreciation, Amortization, and Capitalization</h4> The Company records depreciation and amortization when appropriate using straight-line balance method over the estimated useful life of the assets. The Company estimates that the useful life of necessary equipment is 5 years. Expenditures for maintenance and repairs are charged to expense as incurred. Additions, major renewals and replacements that increase the property's useful life are capitalized. Property sold or retired, together with the related accumulated depreciation is removed from the appropriated accounts and the resultant gain or loss is included in net income.     <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:4.6pt;page-break-after:avoid;text-align:justify;text-justify:inter-ideograph;">Accounts Payable</h4> Accounts Payable discloses a liability to a creditor, carried on open account, usually for purchases of goods and services. The Company had $0 in accounts payable as of April 30, 2020. <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:9.15pt;page-break-after:avoid;text-align:justify;text-justify:inter-ideograph;">Credit Card Liability</h4> Credit card liability represents amounts owed to credit card issuers for money borrowed to pay merchants for goods and services based on the cardholder's promise to pay the card issuer borrowed amounts plus other agreed upon charges. The Company had $8,660 in credit card liability as of April 30, 2020. <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:9.1pt;page-break-after:avoid;text-align:justify;text-justify:inter-ideograph;">Fair Value of Financial Instruments</h4> AS topic 820 "Fair Value Measurements and Disclosures" establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.       The carrying value of cash and the Company's loan from shareholder approximates its fair value due to their short- term maturity. <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:9.15pt;page-break-after:avoid;text-align:justify;text-justify:inter-ideograph;">Income Taxes</h4> Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:9.2pt;page-break-after:avoid;text-align:justify;text-justify:inter-ideograph;">Revenue Recognition</h4> The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers”. The core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity recognizes revenue in accordance with that core principle by applying the following steps: Step 1: Identify the contract(s) with a customer Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price Step 4: Allocate the transaction price to the performance obligations in the contract Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. Specifically, Section 606-10-50 requires an entity to provide information about: a. Revenue recognized from contracts with customers, including the disaggregation of revenue into appropriate categories; b. Contract balances, including the opening and closing balances of receivables, contract assets, and contract liabilities; c. Performance obligations, including when the entity typically satisfies its performance obligations and the transaction price that is allocated to the remaining performance obligations in a contract; d. Significant judgments, and changes in judgments, made in applying the requirements to those contracts. For the three months ended April 30, 2020, the Company generated $0 in revenue. <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:9.2pt;page-break-after:avoid;text-align:justify;text-justify:inter-ideograph;">Basic Income (Loss) Per Share</h4> The Company computes income (loss) per share in accordance with FASB ASC 260 “Earnings per Share”. Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. As of April 30, 2020, there were no potentially dilutive debt or equity instruments issued or outstanding.   <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:4.6pt;page-break-after:avoid;">Comprehensive Income</h4> Comprehensive income is defined as all changes in stockholders' equity (deficit), exclusive of transactions with owners, such as capital investments. Comprehensive income includes net income or loss, changes in certain assets and liabilities that are reported directly in equity such as translation adjustments on investments in foreign subsidiaries and unrealized gains (losses) on available-for-sale securities. As of April 30, 2020, there were no differences between our comprehensive loss and net loss. <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:9.15pt;page-break-after:avoid;">Stock-Based Compensation</h4> Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options. <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:9.15pt;page-break-after:avoid;">Foreign Currency Translation</h4> The Company's functional and reporting currency is the U.S. dollar. Transactions may occur in foreign currencies and management has adopted ASC 830, “Foreign Currency Translation Matters”. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non- monetary assets and liabilities denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Average monthly rates are used to translate revenues and expenses. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the statement of operations. <h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:9.25pt;page-break-after:avoid;">Recent Accounting Pronouncements</h4> Management has reviewed all the recently issued, but not yet effective, accounting pronouncements and does not believe any of these pronouncements will have a material impact on the Company.   In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This guidance changes how companies account for certain aspects of share-based payments to employees. Among other things, under the new guidance, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in-capital (“APIC”), but will instead record such items as income tax expense or benefit in the income statement, and APIC pools will be eliminated. Companies will apply this guidance prospectively. Another component of the new guidance allows companies to make an accounting policy election for the impact of forfeitures on the recognition of expense for share-based payment awards, whereby forfeitures can be estimated, as required today, or recognized when they occur. If elected, the change to recognize forfeitures when they occur needs to be adopted using a modified retrospective approach. All of the guidance will be effective for the Company in the fiscal year beginning February 1, 2017. Early adoption is permitted. The Company is currently evaluating the impact of this guidance, if any, on its financial statements and related disclosures.   In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which issued new guidance related to leases that outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new guidance requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new guidance must be adopted using the modified retrospective approach and will be effective for the Company in the fiscal year beginning February 1, 2019. Early adoption is permitted. The Company is currently evaluating the impact of this guidance, if any, on its financial statements and related disclosures. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The guidance requires an entity to measure inventory at the lower of cost or net realizable value, which is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation, rather than the lower of cost or market in the previous guidance. This amendment applies to inventory that is measured using first-in, first-out (FIFO). This amendment is effective for public entities for fiscal years beginning after December 15, 2016, including interim periods within those years. A reporting entity should apply the amendments prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact of this guidance, if any, on its financial statements and related disclosures.

<h4 style="margin-bottom:3.0pt;margin-left:0in;margin-right:0in;margin-top:12.0pt;page-break-after:avoid;">Note 8 - INCOME TAXES</h4>   As of April 30, 2020, the Company had net operating loss carry forwards of approximately $39,642 that may be available to reduce future years' taxable income in varying amounts through 2041. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred  tax asset relating to these tax loss carry-forwards.   The valuation allowance at April 30, 2020 was approximately $8,325. The net change in valuation allowance during the three months ended April 30, 2020 was $3,727. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized.   The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of April 30, 2020. All tax years since inception remains open for examination by taxing authorities.   The provision for Federal income tax consists of the following:   <div align="left"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:23.85pt;width:439.450012pt;"> <tr style="height:11.5pt;"> <td colspan="3" valign="top" width="76%" style="height:11.5pt;padding:0in 0in 0in 0in;">     April 30, 2020      </td> <td colspan="2" valign="top" width="24%" style="height:11.5pt;padding:0in 0in 0in 0in;">    January 31, 2020 </td> </tr> <tr style="height:11.7pt;"> <td valign="top" width="43%" style="height:11.7pt;padding:0in 0in 0in 0in;"> Non-current deferred tax assets </td> <td valign="top" width="21%" style="height:11.7pt;padding:0in 0in 0in 0in;"> $ </td> <td valign="top" width="12%" style="height:11.7pt;padding:0in 0in 0in 0in;"> - </td> <td valign="top" width="11%" style="height:11.7pt;padding:0in 0in 0in 0in;"> $ </td> <td valign="top" width="13%" style="height:11.7pt;padding:0in 0in 0in 0in;"> - </td> </tr> <tr style="height:11.45pt;"> <td valign="top" width="43%" style="height:11.45pt;padding:0in 0in 0in 0in;"> Net-operating loss carry forwards </td> <td valign="top" width="21%" style="height:11.45pt;padding:0in 0in 0in 0in;">   </td> <td valign="top" width="12%" style="height:11.45pt;padding:0in 0in 0in 0in;"> 8,325 </td> <td valign="top" width="11%" style="height:11.45pt;padding:0in 0in 0in 0in;">   </td> <td valign="top" width="13%" style="height:11.45pt;padding:0in 0in 0in 0in;"> 4,598 </td> </tr> <tr style="height:17.5pt;"> <td valign="top" width="43%" style="height:17.5pt;padding:0in 0in 0in 0in;"> Valuation allowance </td> <td colspan="2" valign="top" width="33%" style="height:17.5pt;padding:0in 0in 0in 0in;">                    (8,325) </td> <td colspan="2" valign="top" width="24%" style="height:17.5pt;padding:0in 0in 0in 0in;">                      (4,598) </td> </tr> <tr style="height:17.3pt;"> <td valign="top" width="43%" style="height:17.3pt;padding:0in 0in 0in 0in;"> Net-deferred tax assets </td> <td valign="top" width="21%" style="height:17.3pt;padding:0in 0in 0in 0in;"> $                                </td> <td valign="top" width="12%" style="height:17.3pt;padding:0in 0in 0in 0in;"> -     </td> <td valign="top" width="11%" style="height:17.3pt;padding:0in 0in 0in 0in;"> $                                  </td> <td valign="top" width="13%" style="height:17.3pt;padding:0in 0in 0in 0in;"> - </td> </tr> </table></div>   The actual tax benefit at the expected rate of 21% differs from the expected tax benefit for the three months ended April 30, 2020 are as follows:   <div align="left"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:23.85pt;width:439.450012pt;"> <tr style="height:11.5pt;"> <td colspan="3" valign="top" width="76%" style="height:11.5pt;padding:0in 0in 0in 0in;">     April 30, 2020      </td> <td colspan="2" valign="top" width="24%" style="height:11.5pt;padding:0in 0in 0in 0in;">    January 31, 2020 </td> </tr> <tr style="height:11.7pt;"> <td valign="top" width="47%" style="height:11.7pt;padding:0in 0in 0in 0in;"> Computed “expected tax expense (benefit) </td> <td valign="top" width="15%" style="height:11.7pt;padding:0in 0in 0in 0in;"> $ </td> <td valign="top" width="14%" style="height:11.7pt;padding:0in 0in 0in 0in;"> (3,727) </td> <td valign="top" width="9%" style="height:11.7pt;padding:0in 0in 0in 0in;"> $ </td> <td valign="top" width="15%" style="height:11.7pt;padding:0in 0in 0in 0in;"> (1,453) </td> </tr> <tr style="height:17.5pt;"> <td valign="top" width="47%" style="height:17.5pt;padding:0in 0in 0in 0in;"> Change in valuation allowance </td> <td colspan="2" valign="top" width="29%" style="height:17.5pt;padding:0in 0in 0in 0in;">                      3,727 </td> <td colspan="2" valign="top" width="24%" style="height:17.5pt;padding:0in 0in 0in 0in;">                        1,453 </td> </tr> <tr style="height:17.3pt;"> <td valign="top" width="47%" style="height:17.3pt;padding:0in 0in 0in 0in;"> Actual tax expense (benefit) </td> <td valign="top" width="15%" style="height:17.3pt;padding:0in 0in 0in 0in;"> $                                </td> <td valign="top" width="14%" style="height:17.3pt;padding:0in 0in 0in 0in;"> -     </td> <td valign="top" width="9%" style="height:17.3pt;padding:0in 0in 0in 0in;"> $                                 </td> <td valign="top" width="15%" style="height:17.3pt;padding:0in 0in 0in 0in;"> -     </td> </tr> </table></div>

The provision for Federal income tax consists of the following:   <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:23.85pt;width:439.450012pt;"> <tr style="height:11.5pt;"> <td colspan="3" valign="top" width="76%" style="height:11.5pt;padding:0in 0in 0in 0in;">     April 30, 2020      </td> <td colspan="2" valign="top" width="24%" style="height:11.5pt;padding:0in 0in 0in 0in;">    January 31, 2020 </td> </tr> <tr style="height:11.7pt;"> <td valign="top" width="43%" style="height:11.7pt;padding:0in 0in 0in 0in;"> Non-current deferred tax assets </td> <td valign="top" width="21%" style="height:11.7pt;padding:0in 0in 0in 0in;"> $ </td> <td valign="top" width="12%" style="height:11.7pt;padding:0in 0in 0in 0in;"> - </td> <td valign="top" width="11%" style="height:11.7pt;padding:0in 0in 0in 0in;"> $ </td> <td valign="top" width="13%" style="height:11.7pt;padding:0in 0in 0in 0in;"> - </td> </tr> <tr style="height:11.45pt;"> <td valign="top" width="43%" style="height:11.45pt;padding:0in 0in 0in 0in;"> Net-operating loss carry forwards </td> <td valign="top" width="21%" style="height:11.45pt;padding:0in 0in 0in 0in;">   </td> <td valign="top" width="12%" style="height:11.45pt;padding:0in 0in 0in 0in;"> 8,325 </td> <td valign="top" width="11%" style="height:11.45pt;padding:0in 0in 0in 0in;">   </td> <td valign="top" width="13%" style="height:11.45pt;padding:0in 0in 0in 0in;"> 4,598 </td> </tr> <tr style="height:17.5pt;"> <td valign="top" width="43%" style="height:17.5pt;padding:0in 0in 0in 0in;"> Valuation allowance </td> <td colspan="2" valign="top" width="33%" style="height:17.5pt;padding:0in 0in 0in 0in;">                    (8,325) </td> <td colspan="2" valign="top" width="24%" style="height:17.5pt;padding:0in 0in 0in 0in;">                      (4,598) </td> </tr> <tr style="height:17.3pt;"> <td valign="top" width="43%" style="height:17.3pt;padding:0in 0in 0in 0in;"> Net-deferred tax assets </td> <td valign="top" width="21%" style="height:17.3pt;padding:0in 0in 0in 0in;"> $                                </td> <td valign="top" width="12%" style="height:17.3pt;padding:0in 0in 0in 0in;"> -     </td> <td valign="top" width="11%" style="height:17.3pt;padding:0in 0in 0in 0in;"> $                                  </td> <td valign="top" width="13%" style="height:17.3pt;padding:0in 0in 0in 0in;"> - </td> </tr> </table>

The actual tax benefit at the expected rate of 21% differs from the expected tax benefit for the three months ended April 30, 2020 are as follows:   <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:23.85pt;width:439.450012pt;"> <tr style="height:11.5pt;"> <td colspan="3" valign="top" width="76%" style="height:11.5pt;padding:0in 0in 0in 0in;">     April 30, 2020      </td> <td colspan="2" valign="top" width="24%" style="height:11.5pt;padding:0in 0in 0in 0in;">    January 31, 2020 </td> </tr> <tr style="height:11.7pt;"> <td valign="top" width="47%" style="height:11.7pt;padding:0in 0in 0in 0in;"> Computed “expected tax expense (benefit) </td> <td valign="top" width="15%" style="height:11.7pt;padding:0in 0in 0in 0in;"> $ </td> <td valign="top" width="14%" style="height:11.7pt;padding:0in 0in 0in 0in;"> (3,727) </td> <td valign="top" width="9%" style="height:11.7pt;padding:0in 0in 0in 0in;"> $ </td> <td valign="top" width="15%" style="height:11.7pt;padding:0in 0in 0in 0in;"> (1,453) </td> </tr> <tr style="height:17.5pt;"> <td valign="top" width="47%" style="height:17.5pt;padding:0in 0in 0in 0in;"> Change in valuation allowance </td> <td colspan="2" valign="top" width="29%" style="height:17.5pt;padding:0in 0in 0in 0in;">                      3,727 </td> <td colspan="2" valign="top" width="24%" style="height:17.5pt;padding:0in 0in 0in 0in;">                        1,453 </td> </tr> <tr style="height:17.3pt;"> <td valign="top" width="47%" style="height:17.3pt;padding:0in 0in 0in 0in;"> Actual tax expense (benefit) </td> <td valign="top" width="15%" style="height:17.3pt;padding:0in 0in 0in 0in;"> $                                </td> <td valign="top" width="14%" style="height:17.3pt;padding:0in 0in 0in 0in;"> -     </td> <td valign="top" width="9%" style="height:17.3pt;padding:0in 0in 0in 0in;"> $                                 </td> <td valign="top" width="15%" style="height:17.3pt;padding:0in 0in 0in 0in;"> -     </td> </tr> </table>

39641

893

8660

9978

3000

6090000

225000000

10902006

17745

8325

4598

-8325

-4598

-3727

-1453

3727

1453

39642

8325

EX-101.SCH 7 none-20200430.xsd 01001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 02001 - Statement - Consolidated Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 02002 - Statement - Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 02003 - Statement - Consolidated Condensed Statements of Operations link:presentationLink link:calculationLink link:definitionLink 02004 - Statement - Consolidated Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 02005 - Statement - Consolidated Statement of Shareholders' Equity(deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 04001 - Disclosure - - ORGANIZATION AND NATURE OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 04002 - Disclosure - - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 04003 - Disclosure - - SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 04004 - Disclosure - - ADVANCE FROM RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 04005 - Disclosure - - COMMON STOCK link:presentationLink link:calculationLink link:definitionLink 04006 - Disclosure - - SELLING, GENERAL AND ADMINISTRATIVE EXPENSES link:presentationLink link:calculationLink link:definitionLink 04007 - Disclosure - - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 04008 - Disclosure - - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 04009 - Disclosure - - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 04010 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 04011 - Disclosure - - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 04012 - Disclosure - - GOING CONCERN (Details Text) link:presentationLink link:calculationLink link:definitionLink 04013 - Disclosure - - SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES (Details Text) link:presentationLink link:calculationLink link:definitionLink 04014 - Disclosure - - ADVANCE FROM RELATED PARTY (Details Text) link:presentationLink link:calculationLink link:definitionLink 04015 - Disclosure - -- COMMON STOCK (Details Text) link:presentationLink link:calculationLink link:definitionLink 04016 - Disclosure - - SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (Details Text) link:presentationLink link:calculationLink link:definitionLink 04017 - Disclosure - - INCOME TAXES (Details 1) link:presentationLink link:calculationLink link:definitionLink 04018 - Disclosure - - INCOME TAXES (Details 2) link:presentationLink link:calculationLink link:definitionLink 04019 - Disclosure - - INCOME TAXES (Details Text) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 none-20200430_cal.xml EX-101.DEF 9 none-20200430_def.xml EX-101.LAB 10 none-20200430_lab.xml Document and Entity Information [Abstract] Document and Entity Information. Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Document Type Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Current Reporting Status Entity Emerging Growth Company Entity Ex Transition Period Entity Filer Category Entity Interactive Data Current Entity Registrant Name Entity Shell Company Entity Small Business Entity Voluntary Filers Entity Well-known Seasoned Issuer - GOING CONCERN [Abstract] GOING CONCERN [Abstract] Going Concern Details [Abstract] - GOING CONCERN [Abstract] GOING CONCERN [Abstract] Going Concern Text Block - GOING CONCERN GOING CONCERN Income Taxes Details [Abstract] - INCOME TAXES [Abstract] INCOME TAXES [Abstract] - ORGANIZATION AND NATURE OF BUSINESS [Abstract] ORGANIZATION AND NATURE OF BUSINESS [Abstract] - SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES [Abstract] SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES [Abstract] Summary Of Signifcant Accounting Policies Details [Abstract] - SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES [Abstract] SummaryOfSignifcantAccountingPoliciesAbstract Accounting Changes and Error Corrections [Text Block] Recent Accounting Pronouncements Significant Accounting Policies (Policies) [Abstract] Accounts Payable and Accrued Liabilities, Current The Company had $0 in accounts payable as of April 30, 2020. Accrued Income Taxes [Abstract] - INCOME TAXES [Abstract] Additional Paid in Capital Additional paid-in capital Additional Paid-in Capital [Member] Additional Paid-In Capital Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by operating activities: Advances to Affiliate The shareholder advance amounted to $9,978 at April 30, 2020. Financing Receivable, Allowance for Credit Loss, Current The valuation allowance at April 30, 2020 was approximately $8,325 Assets, Current Total current assets Assets, Current [Abstract] CURRENT ASSETS Assets, Noncurrent Total assets Basis of Presentation and Significant Accounting Policies [Text Block] - SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES Business Combinations and Other Purchase of Business Transactions, Policy [Policy Text Block] - ORGANIZATION AND NATURE OF BUSINESS Cash CASH AND CASH EQUIVALENTS, BEGINNING OF THE YEAR Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents CASH AND CASH EQUIVALENTS, END OF THE YEAR Cash and Cash Equivalents, Fair Value Disclosure The Company had $893 of cash equivalents as of April 30, 2020. Cash and Cash Equivalents, Period Increase (Decrease) Net increase in cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Commitments and Contingencies COMMITMENTS AND CONTINGENCIES - COMMITMENTS AND CONTINGENCIES [Abstract] Commitments and Contingencies Disclosure [Text Block] - COMMITMENTS AND CONTINGENCIES Common Stock [Member] Common Stock Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] - COMMON STOCK [Abstract] Common Stock, Shares Authorized The number of authorized shares of common stock under the Certificate of Incorporation was adjusted to 225,000,000 shares. Common Stock, Shares, Issued Common stock, $0.001 par value, 225,000,000 and 75,000,000 shares, respectively authorized 10,902,006 and 10,902,006 shares, respectively issued and outstanding Common Stock, Shares, Outstanding Common stock, $0.001 par value, 225,000,000 and 75,000,000 shares, respectively authorized 10,902,006 and 10,902,006 shares, respectively issued and and outstanding Common Stock, Value, Outstanding There were 10,902,006 shares of common stock issued and outstanding as of April 30, 2020. Comprehensive Income (Loss) Note [Text Block] Comprehensive Income Cost of Goods and Services Sold Cost of goods sold Costs and Expenses [Abstract] - SELLING, GENERAL AND ADMINISTRATIVE EXPENSES [Abstract] Credit and Debit Card Receivables, at Carrying Value The Company had $8,660 in credit card liability as of April 30, 2020. Cumulative Earnings (Deficit) The Company has an accumulated deficit of $39,641 and a positive cash flow from operations amounting to $893 for the three months ended April 30, 2020 Current Federal Tax Expense (Benefit) Actual tax expense (benefit) Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Prepaid Expenses - INCOME TAXES (Tables) [Abstract] - INCOME TAXES [Abstract] Deferred Tax Assets, Net of Valuation Allowance Net-deferred tax assets Deferred Tax Assets, Net of Valuation Allowance, Current Non-current deferred tax assets Deferred Tax Assets, Valuation Allowance Valuation allowance Depreciation Depreciation expense Depreciation, Depletion, and Amortization [Policy Text Block] Depreciation, Amortization, and Capitalization Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Stock-Based Compensation Earnings Per Share, Basic and Diluted Net loss per share: Basic and diluted Earnings Per Share [Text Block] Basic Income (Loss) Per Share Employee-related Liabilities, Current Advance from related party Equity Component [Domain] Excess Tax Benefit from Share-based Compensation, Financing Activities Computed "expected tax expense (benefit) Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Federal Income Tax Note [Table Text Block] The provision for Federal income tax consists Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Translation - SELLING, GENERAL AND ADMINISTRATIVE EXPENSES [Abstract] Gross Profit Gross profit from operations Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Net loss from operations before provision for income tax benefit (expense) Income Statement [Abstract] - INCOME TAXES [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Tax Expense (Benefit) Provision for income tax benefit (expense) Income Taxes Paid, Net Income taxes paid Increase (Decrease) in Customer Advances Advance from related party Increase (Decrease) in Deferred Liabilities Credit card liability Increase (Decrease) in Operating Assets [Abstract] Changes in assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses Increase (Decrease) in Regulatory Assets and Liabilities #REF! Interest Paid, Including Capitalized Interest, Operating and Investing Activities Interest expense paid Inventory Disclosure [Text Block] Inventories Inventory, Raw Materials, Gross The Company had $0 in raw materials inventory as of April 30, 2020. Inventory Write-down Inventory Investment Income [Table Text Block] - INCOME TAXES Liabilities Total stockholders' deficit Liabilities and Equity Total liabilities and stockholders' deficit Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities, Current Total current liabilities Liabilities, Current [Abstract] CURRENT LIABILITIES Liabilities, Noncurrent Total liabilities Line of Credit, Current Credit card liability Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Accounts Payable Loss Contingency, Loss in Period Net loss Net Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Net Income (Loss) Attributable to Parent Net loss Operating Cash Flows, Direct Method [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Operating Expenses [Abstract] Operating expenses: Operating Income (Loss) Loss from operations Operating Loss Carryforwards Net-operating loss carry forwards Operating Loss Carryforwards, Valuation Allowance As of April 30, 2020, the Company had net operating loss carry forwards of approximately $39,642 that may be available to reduce future years' taxable income in varying amounts through 2041 Preferred Stock, Value, Issued On January 26, 2017 the Company issued 3,000,000 shares of common stock to a director for cash proceeds Prepaid Expense and Other Assets, Current The Company had $0 in prepaid expenses as of April 30, 2020. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss - ADVANCE FROM RELATED PARTY [Abstract] Related Party Transaction, Due from (to) Related Party, Current [Abstract] - ADVANCE FROM RELATED PARTY [Abstract] Restrictions on Dividends, Loans and Advances [Text Block] - ADVANCE FROM RELATED PARTY Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings [Member] Accumulated Deficit Revenue from Related Parties For the three months ended April 30, 2020, the Company generated $0 in revenue. Revenue Recognition Accounting Policy, Gross and Net Revenue Disclosure [Policy Text Block] Revenue Recognition Revenues Revenues Schedule of Defined Benefit Plans Disclosures [Table Text Block] The actual tax benefit at expected rate Schedule of Line of Credit Facilities [Table Text Block] Credit Card Liability Schedule of Subsequent Events [Table Text Block] - SUBSEQUENT EVENTS Selling Expense For the three months ended April 30, 2020, the Company incurred $17,745 in selling, general and administrative expenses Selling, General and Administrative Expense Selling, general and administrative expenses (Schedule I) Selling, General and Administrative Expenses, Policy [Policy Text Block] - SELLING, GENERAL AND ADMINISTRATIVE EXPENSES Shares, Outstanding Balance (in shares) Balance (in shares) Significant Accounting Policies [Text Block] Basis of presentation Equity Components [Axis] Statement [Line Items] Statement of Cash Flows [Abstract] Statement of Financial Position [Abstract] Statement of Stockholders' Equity [Abstract] Statement [Table] Stock Issued During Period, Shares, Reverse Stock Splits The Stock Split increased the number of shares of common stock from 2,030,000 to 6,090,000 shares - COMMON STOCK [Abstract] Stockholders' Equity Attributable to Parent Balance Balance Stockholders' Equity Note Disclosure [Text Block] - COMMON STOCK - SUBSEQUENT EVENTS [Abstract] Supplemental Cash Flow Information [Abstract] Supplemental cash flow disclosures: Use of Estimates, Policy [Policy Text Block] Use of Estimates Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Change in valuation allowance Weighted Average Number of Shares Outstanding, Diluted Weighted average number of shares outstanding: Basic and diluted EX-101.PRE 11 none-20200430_pre.xml XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 R23.htm IDEA: XBRL DOCUMENT

- INCOME TAXES (Details 1) - USD ($)	Apr. 30, 2020	Jan. 31, 2020
- INCOME TAXES (Tables) [Abstract]
Non-current deferred tax assets	$ 0	$ 0
Net-operating loss carry forwards	8,325	4,598
Valuation allowance	(8,325)	(4,598)
Net-deferred tax assets	$ 0	$ 0

XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R19.htm IDEA: XBRL DOCUMENT

- SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES (Details Text)	3 Months Ended
	Apr. 30, 2020 USD ($)
Summary Of Signifcant Accounting Policies Details [Abstract]
The Company had $893 of cash equivalents as of April 30, 2020.	$ 893
The Company had $0 in prepaid expenses as of April 30, 2020.	0
The Company had $0 in raw materials inventory as of April 30, 2020.	0
The Company had $0 in accounts payable as of April 30, 2020.	0
The Company had $8,660 in credit card liability as of April 30, 2020.	8,660
For the three months ended April 30, 2020, the Company generated $0 in revenue.	$ 0

XML 16 R11.htm IDEA: XBRL DOCUMENT

- COMMON STOCK

3 Months Ended

Apr. 30, 2020

- COMMON STOCK [Abstract]

- COMMON STOCK

Note 5 - COMMON STOCK